Immunovant voluntarily halts studies on sole drug after surprise cholesterol findings, FcRn rival argenx surges
Nearly a year after releasing their first proof-of-concept data, Immunovant’s grand plans for their autoimmune disease antibody have hit a snag.
The Pete Salzmann …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
